This study is looking at how a medication called naltrexone affects the brain's reward system in teenagers and young adults (ages 13-21) with eating disorders that involve binge eating and/or purging. Naltrexone is a drug that blocks the effects of opioids. You would receive a single dose of naltrexone and a single dose of a placebo (an inactive substance) at different times, with a two-week break in between. Researchers will use a special type of brain scan called fMRI (functional magnetic resonance imaging) to see how your brain responds two hours after taking either the naltrexone or the placebo. The goal is to see if fMRI can detect how naltrexone changes activity in specific brain areas related to reward. The study is currently unclear about its recruitment status and plans to enroll 60 participants.

Study design

This is a randomized, placebo-controlled, double-blind, crossover study involving 60 participants. This means you would receive both naltrexone and a placebo at different times, and neither you nor the study staff would know which you are receiving at any given time.

What's involved

You would have two study visits, each involving taking either naltrexone or a placebo, followed by a neuroimaging scan two hours later. There would be a two-week break between these visits.

Compensation

Not stated in the trial record.

Follow-up

Your response will be measured at 2 hours after taking the medication (naltrexone or placebo).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.